#USA #Peabody #Privo Technologies #PRV111 #Oral Cancer

PRV111: Transforming Treatment For Non-Invasive Oral Cancer

In a groundbreaking development in the field of oncology, Privo Technologies has unveiled promising results from its ongoing Phase 2/3 trial of PRV111, a nanoengineered patch designed for the non-surgical treatment of early-stage non-invasive oral cancer and high-grade dysplasias. This innovative approach is set to redefine the treatment landscape for these conditions, which have traditionally relied on surgical excision, often leading to significant patient morbidity and emotional distress.

Efficacy and Results

The trial has yielded impressive results, achieving a 92% complete response (CR) rate. Out of twelve evaluable patients, eleven attained a confirmed pathological CR after a single cycle of treatment with PRV111. The twelfth patient experienced a down-staging from high-grade dysplasia to low-grade, thus circumventing the need for surgery altogether. Notably, all treated mucosal lesions not only resolved but also healed without scarring—a significant improvement over traditional surgical methods that frequently result in scarring and functional impairments in speech and swallowing.

Durable Responses and Monitoring

Long-term monitoring is an integral part of this study. With a median follow-up of approximately six months, no recurrences have been documented, and several patients have maintained their therapeutic responses for up to twelve months. The absence of systemic toxicity further underscores PRV111's favorable safety profile—85% of reported adverse events were mild and transient, primarily consisting of minor oral discomfort, with no serious complications noted.

“PRV111 demonstrates one of the highest complete response rates for localized therapies in this context,” stated Manijeh Goldberg, PhD, MBA, Founder and CEO of Privo Technologies. This approach not only clears pre-cancerous lesions but preserves patients’ native tissues, ensuring the functionality of important oral structures.

A Shift in Treatment Paradigms

The standard treatment for non-invasive oral cancer and high-grade dysplasia has heavily depended on surgical interventions. These surgical procedures often lead to high recurrence rates and can be fraught with complications, including speech impairment and disfigurement. PRV111 offers a non-surgical alternative that administers high concentrations of cisplatin directly to the affected tissue through a brief, office-based application, thereby minimizing systemic side effects traditionally associated with chemotherapy.

Future Directions for PRV111

Privo Technologies is poised to advance PRV111 into a registrational study targeting non-invasive oral cancers and high-grade dysplasias. The company is also keen on exploring PRV111’s application for other early malignant and premalignant conditions, heralding a new era of therapies that prioritize patient comfort and quality of life.

About PRV111

PRV111 is a unique, nanoengineered polymeric patch tailored for delivering concentrated doses of cisplatin directly into oral lesions and surrounding mucosal tissues. This targeted drug delivery method ensures rapid penetration of the drug, maximizing therapeutic efficacy while reducing the likelihood of systemic exposure—an essential consideration in cancer treatment.

Privo Technologies: Innovating for Patient-Centric Care

Privo Technologies stands at the forefront of the clinical development of localized, minimally invasive therapies aimed at treating solid tumors. By leveraging its proprietary nanoengineered delivery platforms, Privo aims to develop therapeutic solutions that not only improve clinical outcomes but also enhance the overall quality of life for patients battling cancer. For additional details, visit Privo Technologies' official site.

As we look to the future, PRV111 symbolizes a significant advancement in the treatment of non-invasive oral cancer, paving the way for less invasive and more effective cancer care options for patients worldwide.